Follow the Pundits
Tag: Funanc1al Edge
Elliott’s 2025 Paradox: Why the Parachute Cost Them the Party
While Wall Street partied through an AI-fueled bull market, Elliott Management showed up wearing a parachute. The result was underperformance — by design. Here’s why Paul Singer’s 2025 wasn’t a failure, but a strategic bet on what comes next.
Principles of Prosperity: How Bridgewater’s AI-Driven “Machine” Built a Fortress in 2025
After years of skepticism, Bridgewater roared back in 2025. Pure Alpha surged, All Weather delivered, and Ray Dalio’s machine pivoted hard into U.S. equities and AI infrastructure. Fortress rebuilt — with a few cracks worth watching.
Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring
CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯
Funds Still Love Meta Platforms — Should Retail Add on Dips?
Funds remain heavily invested in Meta Platforms as AI boosts ads and cash flow — but at today’s price, patience may still pay off.
John Rogers’ Ariel Investments Loves Madison Square Garden Entertainment: Should You?
MSGE owns some of the world’s most iconic entertainment venues. Demand is strong — but leverage and price argue for patience.
Nvidia Is a Top-Five Stock Held by Hedge Funds: Should You Buy — or Even Hold?
Nvidia is the crown jewel of AI and a top hedge-fund holding. The company is stellar — but is the stock still worth buying in 2026?
Hedge Funds Like Royalty Pharma: Should Retail Wear the Crown?
Royalty Pharma isn’t a biotech moonshot — it’s a cash-collecting royalty king. Hedge funds are buying, buybacks are flowing, and dividends keep compounding. 👑💊
Buffett Steps Down as CEO — Should You Step Away from Berkshire?
Buffett steps aside as CEO. The cash pile is massive. The machine still hums. Should long-term investors stay the course with Berkshire Hathaway?
Michael Burry Has 38% of His Portfolio in Lululemon: Time To Wear The Pants?
Michael Burry just made Lululemon a top portfolio holding. With valuation down, buybacks up, and shorts watching — is it time to wear the pants?
Insiders Are Buying Under Armour: Strong Suit or Skip the Knight-Mare?
Under Armour trades over 90% below its all-time high—but insiders are buying aggressively. Is this a rare turnaround opportunity or a classic value trap? Let’s break it down.